Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $5.93 Consensus Price Target from Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.94.

CARM has been the subject of a number of research reports. D. Boral Capital reduced their price objective on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $10.00 to $1.00 in a research note on Thursday. Evercore ISI restated an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday. Finally, HC Wainwright reduced their target price on shares of Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, November 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after purchasing an additional 11,200 shares during the period. Wexford Capital LP raised its stake in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics during the 2nd quarter worth approximately $40,000. Finally, Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. 44.27% of the stock is currently owned by institutional investors and hedge funds.

Carisma Therapeutics Price Performance

Shares of CARM opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. Carisma Therapeutics has a 1-year low of $0.40 and a 1-year high of $3.16. The stock has a market cap of $16.90 million, a PE ratio of -0.26 and a beta of 1.44. The firm has a fifty day moving average price of $0.90 and a 200 day moving average price of $1.03.

Carisma Therapeutics (NASDAQ:CARM) last posted its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The business had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. As a group, sell-side analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.